向的聚合物primaquine纳米颗粒:优化,评估和体内肝脏吸收改善疟疾治疗
Sarvesh Bhargava1,2, Hitesh Kumar Dewangan3, Rohitas Deshmukh1
1Institute of Pharmaceutical Research (IPR), GLA University, Mathura, Uttar Pradesh, India.
Journal of biomaterials science. Polymer edition
|September 1, 2024
概括
这项研究开发了带有primaquine的纳米粒子 (PQ-NP),以改善抗疟疾治疗. 这种纳米配方药物表现出增强的疗效和向性肝脏输送,减少了潜在的副作用.
科学领域:
- 纳米医学是一种纳米医学.
- 制药科学 制药科学
- 疟疾学 疟疾学
背景情况:
- 普里马基因 (PQ) 是一种抗疟疾药物,由于高剂量要求,有显著的毒性问题.
- 纳米配方提供了一种提高药物的生物可用性,疗效和安全性概况的策略.
- 有针对性的药物输送系统对于改善传染病治疗结果至关重要.
研究的目的:
- 为改善抗疟疾疗法开发和表征含有primaquine的聚乳-co-glycolic acid (PQ-NP) 纳米颗粒.
- 评估PQ-NP的体外药物释放和物理稳定性.
- 在Plasmodium berghei疟疾模型中评估PQ-NP的体内疗效,生物分布和毒性.
主要方法:
- 使用修改的双乳液溶剂蒸发技术制备了PQ-NP.
- 纳米粒子的表征包括粒子大小,泽塔潜力,SEM,DSC和FTIR分析.
- 实验室药物释放研究进行了72小时,体内疗效在受感染的小鼠中进行了测试.
主要成果:
- PQ-NP的粒子大小为228nm,正泽塔电位 (+27.4mV) 和高封装效率 (81.3%).
- 实验室释放持续了72小时,DSC显示身体稳定性得到改善.
- 在体内研究表明,与标准普马奎因相比,疗效增加了20%,在肝脏中NP积累了80%.
结论:
- 成功开发PQ-NP作为一种纳米药物输送系统,用于增强抗疟疾治疗.
- PQ-NP提供了一种有前途的策略,以提高治疗效率并减少皮马奎因的不良影响.
- 针对性肝脏积累的PQ-NP表明了改善疟疾寄生虫清除的潜力.
相关概念视频
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
01:29Malaria
Malaria pathogenesis in humans reflects a delicate interplay between parasite biology and host response. Clinical illness reflects a host’s immune response to the parasite’s asexual replication cycle, which is often asymptomatic in individuals with partial immunity. From the parasite's perspective, transmission between mosquito and human with minimal host pathology is evolutionarily advantageous. Among the six Plasmodium species infecting humans, P. falciparum and P. vivax dominate in global...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...